Extradigestive manifestations of IBD in pediatrics

M. ALOI, S. CUCCHIARA

Pediatric Gastroenterology and Hepatology Unit, Department of Pediatrics, University “La Sapienza”, Rome (Italy)

Abstract. – Inflammatory bowel diseases (IBD) are often associated with extraintestinal manifestations (EIMs), which occur in approximately one third of patients. There is only few published data on the occurrence of these manifestations in children and adolescents, so most of the data are taken by studies in adult patients. The organs most commonly affected are joints, skin, eyes and biliary tract, although nearly every organ may be involved. Some of the EIMs are clearly related to intestinal disease activity (i.e. erythema nodosum, peripheral arthritis, orofacial lesions), whereas others occur independently (i.e. pyoderma gangrenosum, anterior uveitis/iritis, ankylosing spondylitis, primary sclerosing cholangitis). Many extraintestinal disorders may be direct inflammatory and metabolic complications of the intestinal inflammation (i.e. osteoporosis, growth retardation, nephrolithiasis, ureteral obstruction, thromboembolic disease).

In this review we provide an overview on the prevalence and clinical aspects of the more commonly reported EIMs of Crohn’s disease and ulcerative colitis in pediatric patients, focusing on specific issues of children affected by IBD (growth failure and metabolic osteopathy).

Key Words: 
IBD, Extradigestive manifestations IBD, Pediatrics IBD.

Introduction

Crohn’s disease (CD) and ulcerative colitis (UC) are systemic disorders that often involve extraintestinal organs. These nonintestinal affections are collectively denominated extraintestinal manifestations and may not always coincide with the underlying bowel disease.

There are only few published data on the occurrence of these manifestations in children and adolescents affected by IBD. The prevalence of EIMs in recent population based studies of patients with IBD ranges from 6% to 47%1-4. Several reports indicate a greater prevalence in children. A recent review by Stawarski et al5 reported that 50% of patients with UC and 80% of those with CD had at least 1 EIM. The organs most commonly involved are joints, skin, eyes and biliary tract, although nearly every organ may be implicated. The pathogenesis of these manifestations is not well understood, but an immunologically mediated mechanism is suggested. It has been hypothesized that antigen cross-reactivity shared by extraintestinal organs may be responsible for some of the extraintestinal localizations of IBD. A key role of the intestinal microflora for the dysregulatory activation of the intestinal immune system and the induction of the chronic inflammatory process in bowel and extraintestinal organs is suggested by animal models. In HLA-B27 transgenic and T cell receptor-α mutant colitis mouse models, the expression of extraintestinal and intestinal disease involve the presence of commensal bacteria; these mouse models do not experience intestinal or extraintestinal inflammation in germfree environments6. Genetic factors have been implicated in the pathogenesis of EIMs in IBD.

EIM, like IBD, have a familial predisposition with a high concordance rate among twins. An association with genes in the HLA region has been established for some of the immunologically mediated extraintestinal manifestations (i.e. uveitis/iritis, primary sclerosing cholangitis, ankylosing spondylitis). For examples, patients with CD who have EIMs are more likely to have HLA-A2, HLA-DR1, and HLA-DQw5, while patients with UC and EIMs...
are more likely to have HLA-DR103, B27, and B58 phenotypes\(^7,8\). Other factors, such as malabsorption, protein-losing enteropathy, intestinal resection, and fistulas can lead to deficiencies of nutrients, proteins, vitamins, and minerals with corresponding clinical consequences. Treatments used in the management of IBD may be associated with many nonintestinal adverse effects.

Extraintestinal manifestations of IBD can be classified in two major groups: the first one includes extradigestive diseases caused by probably immunogenetic mechanisms, and these can be related to intestinal activity disease (i.e. peripheral arthritis, erythema nodosum, aphthous ulcer) or independent to intestinal inflammation (i.e. ankylosing spondylitis, pyoderma gangrenosus, primary sclerosing cholangitis, uveitis); the second one includes inflammatory and metabolic complications of IBD (growth failure, osteoporosis and osteopenia, nephrolithiasis) (Table I). Growth failure and metabolic osteopathy are a clinical challenge every day for pediatric gastroenterologist, worsened by the very frequent rate of these complications in children affected by IBD. An impaired linear growth occurs in more than 35% of CD patients. Metabolic osteopathy (osteoporosis/osteopenia) is observed in 41% of pediatric CD patients and 25% of UC patients\(^9\). In children, IBD may interfere with the attainment and maintenance of peak bone mass, which is the most important determinant of lifelong skeletal health.

**Musculoskeletal Manifestations**

Joint manifestations are the most common EIMs in IBD and occur in about 20%-30% of patients\(^10\). Males and females are equally affected. Symptoms may range from arthralgia to acute arthritis with painful swollen joints. The 2 patterns reported in both children and adults are a peripheral arthritis, and an axial involvement, ankylosing spondylitis or sacroiliitis\(^11\). There are two types of peripheral arthritis in IBD. Type 1 (pauciarticular) arthritis affects less than five large joints (predominantly of the lower limbs) and the swelling is acute and often self-limiting. Type I arthritis is related to disease activity of the underlying bowel disease. The mean duration is 5 weeks. In a report in children, 5 of 32 patients (16%) with UC and 2 of 9 (22%) with CD had peripheral arthritis\(^12\). Type 2 (polyarticular) arthritis is a symmetrical polyarthritis, frequently affecting five or more of the small joints (e.g. knuckle joints). Its course is independent of intestinal disease activity and may last for several months\(^13\). The etiology of peripheral arthritis in IBD is suggested to be a combination of genetic predisposition and exposition to luminal (bacterial) bowel contents. Type 1 IBD arthritis is associated with HLA-DRB1*0103, HLA-B*27 and HLA-B*35, whereas type 2 IBD arthritis is associated with HLA-B*44 and MHC class I chain-like gene A, which is a non classical HLA gene located near the HLA-B on chromosome 6\(^14,15\).

The extension of intestinal inflammation is of particular interest relating the pathogenesis of joint inflammation, as CD patients with colonic involvement are at higher risk of developing arthritis than those with isolated small bowel disease. The axial arthropathies, both spondylitis and isolated sacroiliitis, are rarer than peripheral arthropathy and are reported in 3% to 25% of patients\(^16,17\). Axial arthropathies are not associated with the activity of underlying inflammatory bowel disease. Ankylosing spondylitis is reported in 5% to 10% of patients with IBD\(^18\); most are young (adolescents and young adults) and most are HLA-B27 positive. Ankylosing spondylitis affects the vertebral column by progressive ankylosis of the vertebral facet joints and the sacroiliac joints (bamboo spine). Peripheral arthropathy usually responds to treatment of the underlying colitis. Other therapeutic interventions include

<table>
<thead>
<tr>
<th>Related to intestinal disease activity</th>
<th>Peripheral arthritis</th>
<th>Erythema nodosum</th>
<th>Perianal skin tags</th>
<th>Orofacial lesions</th>
<th>Episcleritis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Independent of intestinal disease activity</strong></td>
<td>Spondylarthrophy</td>
<td>Ankylosing spondylitis</td>
<td>Sacroilitis</td>
<td>Pyoderma gangrenosum</td>
<td>Primary sclerosing cholangitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anterior uveitis, iritis</td>
</tr>
<tr>
<td><strong>Inflammatory and metabolic complications</strong></td>
<td>Growth failure</td>
<td>Osteoporosis, osteopenia</td>
<td>Nephrolithiasis</td>
<td>Ureteral obstruction and fistulas</td>
<td>Haematologic and thromboembolic complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Amyloidosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatitis</td>
</tr>
</tbody>
</table>
rest, physical therapy, and intraarticular steroid injections. For analgetic therapy, nonsteroidal anti-inflammatory drugs and COX-2 inhibitors should be avoided, if possible, due to their potential to activate the underlying IBD.

In contrast to peripheral arthropathy, medical or surgical therapy of the underlying IBD does not modify the natural history of the ankylosing spondylitis. Physical therapy is of particular importance to maintain mobility of the spine. Other treatments have included sulfasalazine, mesalamine, methotrexate, and azathioprine. Experience with anti-TNFalpha is limited to adult case series, but improvement of both spondyloarthropathy and active bowel disease has been reported in CD.

**Osteoporosis/Osteopenia**

Metabolic osteopathy is increasingly identified as a complication of IBD and its treatment in both children and adults. Most, but not all, data suggest that patients with CD are at greater risk than those with ulcerative colitis. In a review osteopenia was found in 41% of children with CD and in 25% with UC. In a study of 42 children, Szumera observed bone-mineral disturbances in 57% of cases, with predominance of osteoporosis in children with CD (24%) and osteopenia in those with UC (24%). In a study about the prevalence of osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment, Walthers reported a rate of osteoporosis of 8% in girls and 20% in boys, similar to adult reports. No-differences were recognized in non-steroid-treated (12%) and steroid-treated (11%) patients. In children, IBD may interfere with the attainment and maintenance of peak bone mass, which is the most important determinant of lifelong skeletal health. Pathogenesis of osteoporosis/osteopenia in IBD is not well understood. Several factors may affect normal bone modeling and remodelling, resulting in decreased bone formation relative to bone resorption. Important potential pathogenetic factors include hypogonadism induced by IBD, malabsorption of calcium and/or vitamin D, low body mass index, corticosteroid exposure, and disease activity with related elevation of inflammatory cytokines. The role of the inflammatory-induced osteopenia has been evaluated and a surface receptor (RANK) localized on osteoclasts that stimulates osteoclastogenesis has been described. Its ligand (RANKL) is induced by proinflammatory cytokines. Osteoprotegerin (OPG) is its decoy receptor and precludes ligation of RANKL to RANK, so preventing bone loss. OPG-RANKL-RANK system has certainly a pivotal role in inflammatory-induced bone loss. Preliminary report about the use of recombinant OPG in inflammation-induced osteoporosis seems to be promising.

Bone density can be evaluated using bone densitometry (e.g., dual energy x-ray absorptiometry). The densimetric criteria for bone loss are based on t and z scores, which are standard-deviation scores expressed in relation to reference values in young healthy subjects (t score) or sex- and age-matched healthy controls (z score). Osteopenia is defined as a score of −1 to −2.5, and osteoporosis is a score lower than −2.5. Patients with CD should undergo baseline bone densitometry scans, with follow-up imaging studies recommended at 1 to 2-year intervals for pediatric patients with long-term, high-dose exposure to corticosteroids. Special attention should be directed to ensuring that patients taking corticosteroids have adequate calcium and vitamin D intakes. Bisphosphonates and calcitonin have been used in adults with IBD for the treatment of osteoporosis, but their use in pediatric patients remains to be demonstrated.

**Mucocutaneous Manifestations**

Skin involvement in IBD is relatively common. The incidence varies from 10% to 15% of patients with IBD. Erythema nodosum, pyoderma gangrenosum and oral ulceration are the most common mucocutaneous manifestations in IBD. Erythema nodosum (EN) is the most frequent skin manifestation in IBD, affecting up to 15% of CD adult patients. A report based on 41 children with IBD found 4 of 32 (12.5%) children with UC and 5 of 9 (56%) with CD had EN. EN presents as a single or multiple tender red nodules typically on the extensor surface of the lower extremities. Normally it heals without ulceration and the prognosis is good. The etiology of EN is unknown. However, there is a genetic association with a distinct HLA region on chromosome 6 (HLA-B15). Treatment of the underlying IBD usually results in improving EN lesions and at least 25% of EN will heal spontaneously.

Pyoderma gangrenosum (PG) occurs in 0.5%-2% of patients with IBD and may take a course independent of disease activity. Specific prevalence data in children are lacking. PG usually begins as a tender erythematous papule that...
spreads rapidly to adjacent skin and develops into a burrowing ulcer with irregular violaceous border, surrounded by an erythematous zone. Lesions are multiple in the majority of patients, and most appear below the knee. PG is found typically on the extensor surfaces of the lower limbs, but may appear in any area of the skin. PG is the most severe skin manifestations in IBD and may develop also before bowel symptoms, during quiescent disease, or even following colectomy. The lesion is painful and often persisting despite adequate therapy. Mild cases usually respond to local and topical therapy, including intralesional corticosteroid, topical cromolyn sodium, and topical 5-aminosalicylic acid. Moderate to severe cases need systemic agents, including oral sulfasalazine, dapsone, corticosteroid, and immunomodulators such as azathioprine, cyclophosphamide, cyclosporine, methotrexate, tacrolimus, and mycophenolate mofetil. Infliximab has shown to be effective in the refractory disease both in children and adults.

Oral aphthous ulcers occur in 10%-30% of patients with IBD and may appear before the onset of intestinal symptoms of IBD or may parallel intestinal disease. The lesions rapidly resolve once remission is achieved.

Metastatic CD is a granulomatous dermatitis seen in adults, whilst sporadic cases have been described in children. Sweet syndrome (acute febrile neutrophilic dermatosis) is a rare EIMs of IBD and presents as tender, erythematous plaques or nodules affecting the arms, legs, trunk, hands, or face. Sweet syndrome secondary to azathioprine hypersensitivity has been rarely reported in patients with IBD. Most cases improve with systemic corticosteroids. Metronidazole has been reported to be effective in 1 case.

Ocular Manifestations

Ocular involvement occurs in 10% of IBD patients. Patients with CD with colonic involvement are more likely to develop ocular problems than those with small bowel disease alone. Data suggest that asymptomatic transient uveitis is frequent in children with IBD, although progression to severe adult uveal disease is poorly reported.

The most common ocular lesions associated with IBD are episcleritis and uveitis. Episcleritis manifests as acute redness, irritation, burning, tender to palpation, without loss of vision. Uveitis can be anterior or posterior. Anterior uveitis is the most common and presents painful eye with visual blurring, and photophobia. Visual acuity is not involved unless the retina or the posterior uveal structures are affected. Diagnosis is made on slit lamp examination, showing flare and cells in the anterior chamber. Ocular manifestation can be improved with the treatment of the underlying bowel disease. Prompt treatment of uveitis with topical or systemic steroids is crucial to prevent progression to blindness. Infliximab has shown efficacy in uveitis, in episcleritis, and scleritis. Ocular complications also may develop in patients with IBD due to chronic corticosteroid usage. Increased intraocular pressure is reported in 22% of pediatric patients treated with corticosteroids. Nevertheless reports of glaucoma also have been reported in children not exposed to corticosteroids, so indicating an immunological mechanism for its development.

Growth Failure

Nutritional issues and failure to thrive are significant problems affecting pediatric IBD patients, especially those with CD. Growth failure often is the initial presenting symptom in children with early-onset disease and can pose an ongoing problem during childhood and adolescence. The presence of growth and pubertal delay is a key factor in the management of pediatric IBD. Maintaining adequate nutrition, minimizing inflammation and maximizing treatment off of corticosteroids remains a crucial part of managing the potential growth stunting effects of active IBD, most specifically small bowel CD. A decrease in height velocity below the third centile has been reported in as many as 88% of CD patients before the diagnosis; in half of this group growth failure was documented before the onset of symptoms attributable to CD. During the clinical course of CD, growth failure has been reported in up to 40% of children with CD and in 6-10% of those with UC. Final height below the fifth centile is reported in 7-30% of adult patients with a pediatric onset of CD. Growth failure in IBD is secondary to several causal agents. Important pathogenetic factors are malnutrition with decreased intake, increased gastrointestinal losses, malabsorption, psychosocial factors and medication effects. All of these components can certainly impact an individual’s nutritional state. Nevertheless, there is increasing evidence that inflammation process per se may directly inhibit linear growth and play a major role in the etiology of growth retardation.
Hepatobiliary Manifestations

The most common serious hepatobiliary complication among pediatric patients is primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease characterized by inflammation and progressive obliterative fibrosis of the intrahepatic and/or extrahepatic bile ducts. Impressive catch-up growth can be observed as soon as remission of intestinal inflammation is achieved. It is essential that height, weight, puberty staging and bone age are accurately and regularly measured and recorded in young patients with IBD. Nutritional supplementation and need for “catch-up” growth should be an important part of the evaluation of a pediatric IBD patient. Exclusive enteral feeding with polymeric feeds for 6-8 weeks has the advantage of combining anti-inflammatory properties with an increase in energy intake, and is thus ideal for patients with growth failure. Administration of growth hormone was examined in a pilot study (7 patients) and did not demonstrate any effect on growth. The effectiveness of infliximab in improving linear growth in pediatric CD patients has been reported.

Genitourinary Manifestations

Nephrolithiasis, obstructive uropathy, and fistulization of the urinary tract are directly associated with the underlying bowel disease activity. Reported incidence varies from 4% to 23% in adult patients. In children with IBD the estimated prevalence is only 1% to 2%. Nephrolithiasis is more frequent in CD than in UC. Calcium-oxalate stones are the most common and are caused by hyperoxaluria due to increased oxalate absorption in the presence of unabsorbed fatty acids in the colon. The fatty acids compete with oxalate to bind calcium, displacing the oxalate, which can then be absorbed as unbound sodium oxalate across colonocytes and excreted into the urine. The sudden onset of severe abdominal (or back or flank) pain in patients with IBD, particularly if different from the usual discomfort, should lead to hypothesize a renal stone in the differential diagnosis.

The management of nephrolithiasis in patients with IBD is similar to that in the general population and consists of analgesia, hydration, and alkalinization of urine for uric-acid stones, lithotripsy, and surgery. Urological manifestations in patients with IBD may include ureteral calculi, enterovesical fistula, perivesical infection, perinephric abscess, and obstructive uropathy with hydronephrosis. Fistulous disease complicating the urinary tract in patients with CD may present with pneumaturia or recurrent uri-
nary tract infections. Glomerulonephritis presenting with proteinuria and hematuria has been reported in children and adults with CD or UC. Diagnosis is by renal biopsy, and treatment is that of the underlying IBD.

A rare complication is renal amyloidosis due to chronic inflammation; it mainly occurs in CD and is rarer in UC. Amyloidosis in patients with IBD often involves the kidney and presents with proteinuria followed by nephritic syndrome and subsequent renal failure or death. The diagnosis is confirmed by detection of amyloid (Congo red staining). Therapy is based on colchicine and renal transplantation.

**Pancreatic Manifestations**

Acute pancreatitis may be associated with both UC and CD. The most common cause is iatrogenic (3% of cases of pancreatitis in IBD patients). Many drugs used in the therapeutic strategy of IBS, such as sulfasalazine, mesalamine, 6-mercaptopurine, and azathioprine, can induce pancreatic injury. Drug-induced pancreatitis typically occurs within the first weeks after starting therapy; the course is mild and usually resolves after discontinuation the drug. Stawarski et al reported acute pancreatitis in 4.5% of children with CD and 5.1% of those with UC. Diagnosis is confirmed by computed tomography with contrast, magnetic resonance imaging, or endoscopic retrograde cholangiopancreatography.

**Hematological Manifestations**

Anemia is the most common hematological manifestation of IBD. Several mechanisms co-exists in the development of the various forms of anemia, including chronic intestinal bleeding, chronic inflammatory disease, inadequate dietary iron intake or absorption, vitamin B12 malabsorption secondary to terminal ileal disease or ileal resection, and folate deficiency due to proximal small-bowel disease or sulfasalazine therapy. Azathioprine and sometimes sulfasalazine and 5-aminosalicylic acid can induce a transitory myelosuppression. In children affected by IBD anemia is reported more frequently in CD (70% of patients) than in UC (5% of patients). Plasma erythropoietin levels often are low in patients with IBD, in conjugation with severe anemia. Treatment of anemia depends on the underlying causes. Symptomatic anemia requires therapy with iron (oral or intravenous), blood transfusion, whilst replacement of deficient vitamins may be required in other types. Recombinant erythropoietin has been successfully used in some patients with IBD and refractory anemia.

Patients with IBD are at increased risk of developing thromboembolic complications. In adults the incidence ranges from 1.2% to 6.1%. Thromboembolism is rarer among children with IBD; Paradis et al have described 3 patients with UC and 1 with CD with thromboembolic complications. Several prothrombotic risk factors, such as immobilization, fluid depletion, inflammation, surgery, steroid therapy, and use of central venous catheters contribute to this increased risk in IBD patients. In active disease the development of thromboses may be related to thrombocytosis and increased concentrations of acute-phase reactants. Inflammatory mediators and hypercoagulation are involved in the pathogenesis of IBD, and some proinflammatory cytokines such as interleukin-6 are thrombogenic. Prevention includes adequate control of disease activity, vitamin supplementation and elimination of removable risk factors.

**Cardiovascular Manifestations**

Pericarditis has been described in a few case reports of children and adults with IBD. The pathogenesis is unknown, but in some cases side events of therapy (e.g., sulfasalazine and mesalamine) have been involved. The clinical symptoms are chest pain, dyspnea, or in severe cases pericardial tamponade.
nisms are proposed for involvement with IBD. Nutritional deficiencies associated with neurological manifestations, such as vitamin B12 deficiency, can be involved. Drugs for treatment of IBD (e.g., metronidazole) also are associated with neurological defects.

Conclusions

This paper has reviewed the epidemiological and clinical characteristics of extraintestinal manifestations of IBD in childhood. IBD are systemic disorders and commonly present extraintestinal manifestations. Almost every organ can be involved by the inflammatory process.

Data related to incidence, prevalence, and clinical presentation of EIMs in children are lacking. The knowledge of these aspects may be essential to improve our understanding of natural history of pediatric IBD. Growth failure and metabolic osteopathy are important issues in the pediatric age group. Prevention, early diagnosis and adequate therapy of EIMs are essential to increase children’s health and quality of life.

References


Extradigestive manifestations of IBD in pediatrics


